GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Pretax Margin %

Immunotech Biopharm (HKSE:06978) Pretax Margin % : % (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Immunotech Biopharm's Pre-Tax Income for the six months ended in Jun. 2024 was HK$-99.64 Mil. Immunotech Biopharm's Revenue for the six months ended in Jun. 2024 was HK$0.00 Mil. Therefore, Immunotech Biopharm's pretax margin for the quarter that ended in Jun. 2024 was %.

The historical rank and industry rank for Immunotech Biopharm's Pretax Margin % or its related term are showing as below:


HKSE:06978's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -123.58
* Ranked among companies with meaningful Pretax Margin % only.

Immunotech Biopharm Pretax Margin % Historical Data

The historical data trend for Immunotech Biopharm's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm Pretax Margin % Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial - - - - -

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunotech Biopharm's Pretax Margin %

For the Biotechnology subindustry, Immunotech Biopharm's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunotech Biopharm's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Pretax Margin % falls into.


;
;

Immunotech Biopharm Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Immunotech Biopharm's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-366.94/0
= %

Immunotech Biopharm's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-99.641/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunotech Biopharm  (HKSE:06978) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Immunotech Biopharm Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunotech Biopharm Business Description

Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Yan Kaijing 2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Cao Longxiang 2201 Interest of corporation controlled by you
Cao Fei 2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Yan Xijun 2501 Other
Wu Naifeng 2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited 2501 Other
Li Yunhui 2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
China Resources Company Limited 2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines